Adenosine triphosphate (ATP) is actively released in the extracellular environment in response to tissue damage and cellular stress. Through the activation of P2X and P2Y receptors, extracellular ATP enhances tissue repair, promotes the recruitment of immune phagocytes and dendritic cells, and acts as a co-activator of NLR family, pyrin domain-containing 3 (NLRP3) inflammasomes. The conversion of extracellular ATP to adenosine, in contrast, essentially through the enzymatic activity of the ecto-nucleotidases CD39 and CD73, acts as a negativefeedback mechanism to prevent excessive immune responses. Here we review the effects of extracellular ATP and adenosine on tumorigenesis. First, we summarize the functions of extracellular ATP and adenosine in the context of tumor immunity. Second, we present an overview of the immunosuppressive and pro-angiogenic effects of extracellular adenosine. Third, we present experimental evidence that extracellular ATP and adenosine receptors are expressed by tumor cells and enhance tumor growth. Finally, we discuss recent studies, including our own work, which suggest that therapeutic approaches that promote ATP-mediated activation of inflammasomes, or inhibit the accumulation of tumorderived extracellular adenosine, may constitute effective new means to induce anticancer activity.
Introduction
For many scientists in the 1960s, cells could not possibly release a molecule as fundamental as adenosine triphosphate (ATP). Owing to its established role in the Krebs cycle, there was considerable skepticism to the notion that ATP-and purines in general-could exert extracellular function. In 1970, Burnstock et al. described the release of extracellular ATP as a transmitter substance by non-adrenergic inhibitory nerves, and later in 1972, formulated the hypothesis of purinergic neurotransmission (Burnstock, 1972 ). Burnstock's hypothesis that ATP could be released by cells to perform intercellular signaling was initially met with skepticism, as it seemed unlikely that a molecule that acts as an intracellular source of energy would also function as an extracellular messenger. Nevertheless, Burnstock pursued his work and, together with Che Su and John Bevan, reported that ATP was also released from sympathetic nerves during stimulation (Su et al., 1971) . Three decades later, following the cloning and characterization of ATP and adenosine cell surface receptors, purinergic signaling is a well-established concept and constitutes an expanding field of research in health and disease, including cancer (Burnstock, 2007) . Although early studies focused on the role of purinergic receptors in neurotransmission, it soon became obvious that extracellular ATP and adenosine have important roles in another system requiring efficient cell-to-cell communication: the immune system. Over the last decade, there has been increasing interest not only in the effects of extracellular purines and pyrimidines on inflammatory responses, but also on general biological pathways, such as cell survival, proliferation, differentiation and motility. It is becoming increasingly clear that the release of extracellular purines and pyrimidines represents a ubiquitous means of intercellular communication used by different cell types, involved in various biological processes and conserved throughout evolution, as evidenced by the discovery of ATP receptors in invertebrates (Fountain et al., 2007) and plants (Kim et al., 2006) .
Extracellular ATP in immunity

ATP receptors
In 1978, Burnstock proposed two types of purinergic receptors: P1 receptors selective for adenosine and P2 receptors selective for ATP and ADP. Some P2 receptors additionally bind UTP or UDP (Burnstock, 2006) . In 1985, a pharmacological approach was proposed to distinguish between two types of P2 receptors: ionotropic P2X and metabotropic P2Y receptors. Currently, four subtypes of P1 receptors (A1, A2A, A2B and A3), seven subtypes of P2X receptors and eight subtypes of P2Y receptors have been identified (Figure 1 ). P2Y receptors are subdivided into five G q/ G 11 -coupled subtypes (P2Y 1 , P2Y 2 , P2Y 4 , P2Y 6 and P2Y 11 ) and three G i/o -coupled subtypes (P2Y 12 , P2Y 13 and P2Y 14 ). G q/ G 11 -coupled P2Y receptors generally activate the phospholipase C and inositol triphosphate pathways, whereas G i/o -coupled P2Y receptors generally inhibit adenylyl cyclase and modulate ion channels (Abbracchio et al., 2009) .
In contrast to G-protein-coupled P2Y receptors, P2X receptors are trimeric cationic channels permeable to Na þ , K þ and Ca 2 þ upon activation. Six homomeric (P2X 1À5 and P2X 7 ) and six heteromeric (P2X 1/2 , P2X 1/4 , P2X 1/5 , P2X 2/3 , P2X 2/6 and P2X 4/6 ) receptors have been described. The homomeric P2X 7 receptor is an atypical purinergic receptor with a longer carboxy-terminal tail and a number of polymorphisms or spliced variants (Gunosewoyo et al., 2007; Wu et al., 2009) . The activation of P2X 7 receptors is highly regulated by extracellular levels of ATP. Whereas low ATP concentrations activate P2X 7 ion channels to become permeable to small ions, high ATP concentrations result in pore formation permeable to molecules as large as 900 kDa, which ultimately causes cell death (Khakh and North, 2006) . Extracellular ATP and the NLR family, pyrin domain-containing 3 inflammasome In the context of inflammation, the release of ATP by activated monocytes, dying, injured or stressed cells, degranulating platelets or secreted by bacteria themselves, acts as a co-activator of the NLR family, pyrin domain-containing 3 (NLRP3) (cryopirin/NALP3) inflammasome (Piccini et al., 2008; Netea et al., 2009) . The NLRP3 inflammasome is a multiprotein complex that triggers caspase-1 activation (Mariathasan et al., 2006) and the processing and secretion of the cytokines interleukin-1b (IL-1b) and IL-18, important activators of innate and adaptive immune responses. The NLRP3 inflammasome is the best-characterized inflammasome and belongs to the intracellular NOD-like receptor (NLR) family. Together with Toll-like receptors (TLRs) and C-type lectins, NLRs scan the extracellular and intracellular environment for pathogen-associated molecular patterns and host-derived danger-associated molecular patterns to alert the immune system (Schroder and Tschopp, 2010) . The NLRP3 inflammasome is activated in response to various danger signals, such as co-activation of P2X 7 and TLRs, increased cytosolic DNA levels, monosodium urate crystals, fibrillar amyloid-b peptide and high extracellular glucose levels (Schroder and Tschopp, 2010) . The NLRP3 inflammasome can also be activated independently of TLR signaling (Kanneganti et al., 2007) . Schroder and Tschopp (2010) recently proposed that a unifying element in NLRP3 activation might be the generation of reactive oxygen species. The activation of P2X 7 receptors and the recruitment of the pannexin-1 membrane pore may also allow NLRP3 agonists to enter the cells and directly activate the inflammasome (Kanneganti et al., 2007) .
Extracellular ATP and T helper type 17 cell immune responses T-helper type 17 cell immune responses are required for the control of infectious agents (Cho et al., 2010) and are involved in the pathogenesis of various autoimmune diseases, such as multiple sclerosis (Axtell et al., 2010) Figure 1 Adenosine triphosphate (ATP) and adenosine receptor signaling. Extracellular ATP binds G-protein-coupled P2Y and trimeric ion channel P2X receptors. P2Y receptors are subdivided into G q/ G 11 -coupled subtypes that activate the phospholipase C and inositol triphosphate pathways, and G i/o -coupled subtypes that inhibit adenylyl cyclase. P2X 7 is an atypical ATP receptor, forming ion channels at low concentrations of ATP, activating NLRP3 inflammasomes by K þ efflux and the recruitment of the pannexin-1 hemichannel, and inducing cell death at high concentrations of ATP. Extracellular adenosine binds G i/o -coupled A1 and A3 receptors and G s -coupled A2A and A2B receptors. In contrast to A1 and A3 receptors, A2A and A2B receptors increase intracellular cyclic AMP levels. and inflammatory bowel disease (Cho and Weaver, 2007) . The generation of Th17 cells is controlled by the cytokines IL-6, tumor growth factor (TGF)-b and IL-23 (Bettelli et al., 2007) . 'Naturally occurring' IL-17-producing CD4 þ T cells are also present in the gut. Atarashi et al. (2008) recently investigated the contribution of commensal bacteria in the development of Th17 cells. Surprisingly, the study showed that extracellular ATP is constitutively released from commensal bacteria and drives the differentiation of Th17 CD4 þ cells. This Th17-skewing effect of extracellular ATP has also been shown in monocyte-derived dendritic cells (DCs) (Schnurr et al., 2005) . Thus, excessive accumulation of extracellular ATP may have an important role in the pathogenesis of autoimmune diseases. In support of this hypothesis, mice deficient for the ecto-nucleoside triphosphate diphosphohydrolase, CD39, which hydrolyzes ATP, develop exacerbated experimental colitis (Friedman et al., 2009) . Moreover, patients with low levels of CD39 activity have an increased susceptibility for developing Crohn's disease (Friedman et al., 2009) . Taken together, these studies are consistent with a role for extracellular ATP in driving Th17 immune responses.
Extracellular ATP and chemotaxis
Activation of the ATP receptor P2Y 2 has been recently implicated in the directed migration (that is, chemotaxis) of immune phagocytes, such as macrophages and neutrophils. However, the means by which P2Y 2 regulate the chemotaxis of macrophages and neutrophils are markedly different. In monocytes/macrophages, extracellular ATP released from an extrinsic source, such as apoptotic cells, directly acts as a 'find-me' signal (Elliott et al., 2009) . In contrast, migrating neutrophils do not migrate toward gradients of ATP, but release ATP at their leading edge in response to a chemoattractant, which, through the feedback activation of P2Y 2 and A3 receptors, provides chemotaxis amplification (Chen et al., 2006) . Thus, whereas both macrophages and neutrophils exploit P2Y 2 signaling, only in macrophages does it stimulate a non-redundant chemotactic signal. Extracellular 'find-me' signals, such as ATP, act in concert with 'keep-out' signals to induce macrophage recruitment. For instance, the release of lactoferrin selectively inhibits the migration of granulocytes, but not macrophages (Bournazou et al., 2009) . These recent studies offer a new level of complexity to the mechanisms governing cellular chemotaxis. The generally conserved functions of purinergic receptors and their ubiquitous expression in different tissues suggest that ATP and adenosine receptors may be implicated in the motility of other cell types, including tumor cells.
Extracellular ATP and dendritic cells
Although monocytes and macrophages are generally responsible for the non-immunogenic removal of apoptotic cells, DCs are specialized antigen-presenting cells whose role is to initiate or regulate immune responses. Extracellular ATP, by activation of P2Y receptors, has been identified as a potent chemotactic stimulus for immature DCs (Idzko et al., 2002) . In contrast, mature DCs exposed to ATP have decreased migratory capacity (Schnurr et al., 2003) . Thus, the accumulation of ATP at sites of infection may allow the recruitment of immature DCs. The transient inhibition of DCs' migration after maturation might then prolong antigen encounter. However, extensive exposure to extracellular ATP can also inhibit DC functions. ATPstimulated human DCs produce less pro-inflammatory cytokines, more IL-10 and synergize with interferon (IFN)-g in upregulating indoleamine 2,3-dioxygenase levels (Marteau et al., 2005) .
Extracellular adenosine in immunity
Adenosine receptors
The conversion of extracellular ATP to adenosine, essentially through the enzymatic activity of the membrane-bound nucleotidases CD39 and CD73, acts as a negative-feedback mechanism that prevents excessive immune reactions. The immunosuppressive effects of adenosine are summarized in Figure 2 . Extracellular adenosine activates four distinct G-protein-coupled receptors: G i/o -coupled A1 and A3 receptors that decrease intracellular cyclic AMP (cAMP) levels, and G s -coupled A2A and A2B receptors that increase cAMP levels through the activation of adenylyl cyclase (Hasko and Cronstein, 2004) . In contrast to the other adenosine receptors, which are all activated at physiological concentrations of adenosine (that is, 30-300 nM in interstitial fluid), the A2B receptor requires high levels of adenosine generated in response to pathological conditions (Fredholm et al., 2001) .
Adenosine receptor signaling A1 and A3 adenosine receptors inhibit adenylyl cyclase and protein kinase A activity, thus decreasing intracellular cAMP levels, with studies revealing an important function in cardioprotection (Liang and Jacobson, 1998; Reichelt et al., 2005; Hochhauser et al., 2007) , angiogenesis (Clark et al., 2007) and protection against septic shock (Gallos et al., 2005) . A1 and A3 adenosine receptors have also been linked to phosphatidylinositol 3-kinase, mitogen-activated protein kinase and protein kinase C pathways (Hasko and Cronstein, 2004; Gessi et al., 2008) . In contrast to other P1 receptors, A3 adenosine receptor presents multiple sites of phosphorylation that are important for receptor desensitization after activation (Palmer and Stiles, 2000) .
A2A and A2B adenosine receptors activate adenylyl cyclase and protein kinase A, thereby increasing intracellular cAMP levels (Fredholm et al., 2007) . A2A and A2B receptors can further activate mitogenactivated protein kinase and protein kinase C. Owing to its high affinity for adenosine, the A2A adenosine receptor has a non-redundant immunosuppressive role (Ohta and Sitkovsky, 2001; Odashima et al., 2005) . The A2A adenosine receptor is expressed on monocytes/ macrophages, mast cells, granulocytes, lymphocytes, DCs, natural killer (NK) cells, natural killer T (NKT) cells, endothelial cells and airway epithelial cells (Fredholm et al., 2007) . Importantly, the regulation of A2A receptor expression is driven by at least four independent promoters (Yu et al., 2004) , which most likely accounts for tissue-specific functions. A2A receptor expression is induced by hypoxia, as well as by tumor necrosis factor (TNF)-a and IL-1a by nuclear factor-kB (Khoa et al., 2001) . The A2B adenosine receptor differs from the other adenosine receptors by its relative low affinity for adenosine (Feoktistov and Biaggioni, 1997) . A2B is transcriptionally induced by hypoxia-inducible factor-1a activation (Eltzschig et al., 2003; Feoktistov et al., 2004) , TNF-a, IL-1b, IFN-g and extracellular adenosine (Xaus et al., 1999; Kolachala et al., 2005; St Hilaire et al., 2008) .
Adenosine-mediated immunosuppression
Effect of adenosine on immune phagocytes. The accumulation of extracellular adenosine profoundly inhibits the function of phagocytes. In macrophages, adenosine inhibits phagocytosis, production of superoxide and nitric oxide (Eppell et al., 1989) (Hasko et al., 1996) , TNF-a release, major histocompatibility complex class II expression and IL-12 production (Hasko et al., 2000) . In neutrophils, adenosine inhibits degranulation, adhesion to endothelial cells and superoxide production (Cronstein et al., 1990; Firestein et al., 1995; Bouma et al., 1997) .
Effect of adenosine on NK cells. In contrast to macrophages and neutrophils, the effect of extracellular adenosine on NK cells is not as clearly defined. The activation of A3 adenosine receptors have been shown to enhance NK cell functions, although this could be the result of chronic exposure to A3 agonists that induce receptor desensitization (Priebe et al., 1990; Harish et al., 2003) . In contrast, activation of A2A adenosine receptor has been shown to inhibit IFN-g production (Lappas et al., 2005) . The inhibitory effect of the A2A receptor on NK cells most likely reflects its ability to increase intracellular cAMP levels, which has been shown to suppress NK cell functions (Goto et al., 1983) .
Effect of adenosine on NKT cells. Natural killer T cells are a unique population of T cells involved in the regulation of autoimmunity, infection, immune tolerance and tumor immunosurveillance (Godfrey and Kronenberg, 2004; Swann et al., 2009) . NKT cells recognize glycolipids presented in the context of the major histocompatibility complex class I-like molecule CD1d and produce large amounts of cytokines upon activation. NKT cells deficient in A2A adenosine receptor were found to produce significantly less IL-4, IL-10 and TGF-b, but more IFN-g upon stimulation with alpha-galactosylceramide (Nowak et al., 2010) . Consistent with a role for adenosine in regulating NKT Figure 2 Immunosuppressive effects of extracellular adenosine. The phosphohydrolysis of extracellular adenosine triphosphate (ATP) to adenosine, essentially through the activity of the ecto-nucleotidases CD39 and CD73, acts as a potent negative-feedback mechanism to suppress the functions of innate and adaptive immune cells.
cell function, CD39-deficient NKT cells have been shown to produce less IL-4 upon activation (Beldi et al., 2008) .
Effect of adenosine on DCs. Extracellular adenosine increases the chemotaxis of immature monocyte-derived DCs, but inhibits IL-12 production following activation (Panther et al., 2001 (Panther et al., , 2003 . Similarly, immature plasmacytoid DCs also migrate toward a gradient of adenosine (Schnurr et al., 2004) . Upon maturation, DCs alter the expression profile of adenosine receptors, switching from Gi-to G s -coupled receptors, resulting in a loss of chemotactic response and an inhibition of cytokine-producing function (Schnurr et al., 2004) . Recently, Novitskiy et al. (2008) investigated the effect of extracellular adenosine on the differentiation of human DCs from blood monocytes. The activation of A2B adenosine receptors on monocytes was shown to divert DC differentiation toward a population that produced high levels of vascular endothelial growth factor, IL-8, IL-6, IL-10, cyclooxygenase-2, TGF-b and indoleamine 2, 3-dioxygenase. Remarkably, when adoptively transferred to tumor-bearing mice, adenosinedifferentiated DCs significantly enhanced tumor growth.
Effect of adenosine on B cells. The activation of A2A adenosine receptors, by increased protein kinase A activity, has been shown to inhibit B-cell receptorinduced NF-kB activation (Minguet et al., 2005) . Consistent with a role for adenosine in regulating B-cell functions, isotype-switched B cells, and more specifically a subpopulation of memory B cells, upregulate the expression of CD73, an essential ecto-nucleotidase for the generation of extracellular adenosine (Anderson et al., 2007) . Further in support of this model, a recent study revealed that memory B cells have increased expression of genes involved in adenosine signaling, including A2A adenosine receptor, compared with naive B cells (Tomayko et al., 2008) . Taken together, these studies strongly suggest that isotypeswitched B cells, especially memory B cells, use adenosine receptors to control antigenic re-stimulation.
Effect of adenosine on T cells. Extracellular adenosine is also an important inhibitor of T-cell functions. Similar to its effect on B cells, adenosine inhibits T-cell receptorinduced NF-kB activation (Majumdar and Aggarwal, 2003) . The A2A receptor dominantly regulates T-cell functions and is significantly upregulated upon T-cell activation. Activation of A2A receptors during T-cell activation significantly inhibits cytotoxicity and cytokine production (Ohta et al., 2009 ) and has been reported to inhibit T-cell proliferation (Zhang et al., 2004; Deaglio et al., 2007) . T cells activated in the presence of an A2A receptor agonist maintain a suppressed phenotype after removal of the agonist (Ohta et al., 2009) . A2A receptor activation in T cells suppresses the development of both Th1 and Th2 immune responses, in vitro and in vivo (Csoka et al., 2008) . When activated in the presence of an A2A receptor agonist, T cells fail to proliferate and to produce IFN-g upon reactivation, thus essentially promoting T-cell anergy (Zarek et al., 2008) . In vivo activation of A2A adenosine receptors drives CD4 þ T-cell differentiation toward Foxp3 þ regulatory T cells (Tregs), most likely owing to a concomitant increase in TGF-b and decrease in IL-6 production following A2A receptor activation (Zarek et al., 2008) . In addition, activation of A2A receptors was found to promote the generation of LAG-3 þ Tregs.
Adenosine and Tregs. þ Tregs express high levels of both CD39 and CD73, upregulate CD73 upon activation, and partly rely on ecto-nucleotidase activity and adenosine for immunosuppression (Ring et al., 2010) . Human Foxp3 þ Tregs also express CD39, which is further upregulated upon Treg activation (Miyara et al., 2009) , whereas CD73 expression remains unclear. The analysis of CD73 expression may be affected by antibody-mediated shedding (Airas et al., 1997) . Nevertheless, inhibition of CD73 has been shown to reduce human Treg-mediated suppression in vitro (Mandapathil et al., 2010) . A recent study has further identified extracellular ATP as an activating molecule of Tregs (Ring et al., 2010) . Thus, extracellular release of ATP and its hydrolysis to adenosine by CD39 and CD73 have a crucial role in Treg function.
Production of extracellular adenosine. The extracellular concentration of adenosine is generally constant in most tissues, but can rapidly increase 100-fold in hypoxic tissue and in response to inflammation (Schulte and Fredholm, 2003) . The dominant pathway leading to high extracellular adenosine levels is the extracellular phosphohydrolysis of ATP by ecto-nucleotidases. These include ecto-nucleoside triphosphate diphosphohydrolases, ecto-nucleotide pyrophosphatase and phosphodiesterases, alkaline phosphatases and CD73 (ecto-5 0 -nucleotidase). Ecto-nucleoside triphosphate diphosphohydrolases (predominantly CD39) and ectonucleotide pyrophosphatase and phosphodiesterases hydrolyze ATP and ADP to AMP, which is further hydrolyzed to adenosine by CD73. Thus, the membranebound nucleotidases CD39 and CD73 are key regulators of the phosphohydrolysis of ATP into adenosine.
CD39 (NTPDase1) is expressed on endothelial cells and subsets of leukocytes, where it hydrolyzes ATP and ADP released by activated platelets, thereby inhibiting platelet recruitment and thrombus formation (Robson et al., 2006) . CD39 expression on leukocytes also regulates leukocyte migration across the endothelium into ischemic tissue (Hyman et al., 2009) . CD39 also has important immunosuppressive functions through the phosphohydrolysis of pro-inflammatory extracellular ATP and the generation of extracellular adenosine when co-expressed together with CD73 .
CD73 (ecto-5
0 -nucleotidase) The membrane-bound CD73 (or ecto-5 0 -nucleotidase) is considered as the rate-limiting enzyme in the generation of extracellular adenosine (Resta et al., 1998) . CD73 catalyzes the dephosphorylation of purine and pyrimidine ribo-and deoxyribonucleoside monophosphates to the corresponding nucleoside. CD73 expression is upregulated by hypoxia-inducible factor-1a activation and exposure to type I IFNs, and has been associated with Wnt signaling (Synnestvedt et al., 2002; Niemela et al., 2004; Spychala and Kitajewski, 2004) and protein kinase C activation (Kitakaze et al., 1996) . In addition, IL-1b, TNF-a and prostaglandin E2 have been shown to enhance CD73 activity, whereas IFN-g and IL-4 have been shown to downregulate CD73 (Savic et al., 1990; Christensen et al., 1992) . The structure of CD73 has been reviewed elsewhere (Strater, 2006) . CD73 functions. CD73 is expressed on various cell types, including subsets of lymphocytes, endothelial cells and epithelial cells (Colgan et al., 2006) . The expression of CD73 is critical for the regulation of hypoxia-induced vascular leakage and for the control of inflammatory responses (Thompson et al., 2004) . CD73 upregulation on endothelial cells decreases endothelial vascular cell adhesion molecule-1 expression and prevents leukocyte attachment. CD73 expression on high endothelial venules also negatively regulates the migration of T and B cells from the blood into draining lymph nodes in response to TLR4 activation (Takedachi et al., 2008) . In contrast to its role in lymph nodes, CD73 promotes T-cell extravasation in peripheral tissue. Accordingly, decreased extravasation of pathogenic T cells was recently suggested as the cause of resistance of CD73-deficient mice to experimental autoimmune encephalomyelitis (Mills et al., 2008) . Through the production of adenosine and the activation of adenosine receptors on endothelial cells, it was suggested that CD73 triggers adhesion molecules, such as intercellular adhesion molecule 1 on endothelial cells.
In addition to its enzymatic function, CD73 has been suggested to have a role in T-cell signaling (Resta et al., 1998) and cell adhesion. Human T cells treated with a plate-bound anti-CD73 monoclonal antibody and submitogenic concentrations of anti-CD3 monoclonal antibody proliferate more readily and produce more IL-2 (Massaia et al., 1990) . CD73 has been shown to regulate T-cell adhesion in a mechanism dependent on lymphocyte function-associated antigen-1 (Airas et al., 2000) . CD73 has also been shown to interact directly with extracellular matrix proteins, such as laminin, fibronectin and tenascin C (Dieckhoff et al., 1986; Sadej et al., 2006) . CD73 on cancer cells. CD73 has been found to be overexpressed in several types of cancer, including bladder cancer (Stella et al., 2010), leukemia (Mikhailov et al., 2008) , glioma (Bavaresco et al., 2008) , glioblastoma (Ludwig et al., 1999) , melanoma (Sadej et al., 2006) , ovarian cancer (Jin et al., 2010) , thyroid cancer (Kondo et al., 2006) , esophageal cancer (Fukuda et al., 2004) , gastric cancer (Durak et al., 1994) , colon cancer (Eroglu et al., 2000) , prostate cancer and breast cancer . Notably, CD73 expression has been associated with a pro-metastatic phenotype in melanoma and breast cancer (Lee et al., 2003; LethLarsen et al., 2009) . In breast cancer cells, CD73 expression was regulated by estrogen receptor-a, whereby loss of estrogen receptor-a significantly enhanced CD73 expression . In addition, CD73 expression was increased in breast tumor cells resistant to doxorubicin (Ujhazy et al., 1996) . CD73 also increased the resistance of Jurkat leukemic cells to tumor necrosis factor-related apoptosis-inducing ligandmediated apoptosis (Mikhailov et al., 2008) .
Purinergic signaling in cancer
Tumor-suppressive effects of extracellular ATP Owing to its pro-inflammatory role and its direct cytotoxic function, the ATP receptor P2X 7 might act as a tumor suppressor. Consistent with this hypothesis, P2X 7 levels are significantly lower in various types of cancer cells compared with adjacent normal tissues of the same origin . In addition, P2X 7 receptors have been found to be cytolytically nonfunctional in tumor cells (Slater et al., 2004) . Several mechanisms regulate P2X 7 -induced cell death, including glycosylation (Feng et al., 2005) , trafficking (Guerra et al., 2003) , oligomerization and internalization . In support of a selective advantage for tumor cells with decreased P2X 7 levels, a recent study identified putative target sites for micro-RNA-186 and micro-RNA À150 within the P2X 7 gene, and showed that micro-RNA À186 and micro-RNA À150 levels are significantly higher in cancer cells than in normal cells (Zhou et al., 2008) . More evidence that P2X 7 may act as a tumor suppressor comes from the analysis of breast cancer patients with a genetically dysfunctional P2X 7 . Breast cancer patients harboring a P2X 7 gene associated with decreased P2X 7 activity have a significantly greater risk of progression to metastatic disease (Ghiringhelli et al., 2009) . Taken together, these studies support a tumor-suppressive role for P2X 7 .
Pro-tumorigenic effects of extracellular ATP Other studies, in contrast, suggest that extracellular ATP can promote tumor growth, either directly by activation of P2 receptors on tumor cells (including P2X 7 ) or indirectly via non-transformed cells. During skin wound healing, the release of extracellular ATP has been shown to be critical for efficient epithelial repair, revealing the role of purinergic signaling in general cell functions. Indeed, activation of ATP receptors stimulates the proliferation of epidermal keratinocytes (Greig et al., 2003) and smooth muscle cells (Wilden et al., 1998) , and initiates migration of epithelial cells (Boucher et al., 2007) . Likewise, extracellular ATP released from hepatocytes and Kupffer cells immediately after hepatectomy has been shown to promote liver regeneration (Gonzales et al., 2010) . One mechanism by which extracellular ATP enhances cell function is through the transactivation of epidermal growth factor receptor (EGFR). G-protein-coupled receptors are important transactivators of EGFR, thereby promoting cell survival and proliferation. A recent study has identified a P2Y-dependent pathway (most likely P2Y 2 ) that leads to the release of the EGFR ligand TGF-a and transactivation of EGFR, through a mechanism involving mitochondrial production of reactive oxygen species (Myers et al., 2009) . Interestingly, other groups have also reported the ability of P2Y 2 to induce reactive oxygen species, including in prostate cancer cells, resulting in increased tumor growth (Sauer et al., 2001) . Although transactivation of EGFR can trigger kinase-dependent pathways, it may further promote cell survival independently of its kinase activity. Indeed, recent studies have shown that EGFR maintains basal intracellular glucose levels in a kinase-independent manner (Weihua et al., 2008) . Whether extracellular ATP can maintain intracellular glucose levels by EGFR transactivation remains unknown. However, it has been observed that activation of purinergic receptors increases intracellular ATP content (Di Virgilio et al., 2009) . The activation of P2X 7 has also been shown to increase tumor cell survival. Accordingly, overexpression of P2X 7 increased cell survival in serum-free conditions, whereas blocking P2X 7 suppressed proliferation of lymphocytic leukemia cells (Adinolfi et al., 2002) . Taken together, these studies suggest that accumulation of extracellular ATP can induce important pro-tumorigenic effects.
In addition to its direct effect on tumor cells, extracellular ATP may support tumor growth and metastasis by indirect means by activation of purinergic receptors on non-transformed cells. Chronic exposure of C6 glioma cells to ATP, for instance, enhances the release of the pro-inflammatory factors MCP-1, IL-8 and vascular endothelial growth factor (Jantaratnotai et al., 2009) . In thyroid papillary carcinoma cells, P2X 7 activation induces IL-6 production (Solini et al., 2008) . P2X 7 has also been shown to trigger the release of the growth factor substance P from neuroblastoma cells (Raffaghello et al., 2006) . Finally, activation of P2X 7 in C6 glioma cells has been shown to increase tumor cell migration (Wei et al., 2008) .
Adenosine receptors in cancer A1 receptors in cancer. A1 adenosine receptors have been found to be overexpressed in primary breast tumor tissues and to enhance breast cancer cell proliferation (Mirza et al., 2005) . RNA interference knockdown studies suggested that activation of A1 adenosine receptors decreases p27 expression, thereby upregulating CDK4 activity (Mirza et al., 2005) . The activation of A1 adenosine receptors may thus contribute to resistance against trastuzumab (Herceptin) therapy, which relies on p27 upregulation (Lane et al., 2001) . A1 adenosine receptor has also recently been shown to act as a target and regulator of estrogen receptor-a in breast cancer cells (Lin et al., 2010) .
A3 receptors in cancer. A3 receptor is also upregulated in transformed versus adjacent non-transformed cells (Madi et al., 2004) . In the case of A3 adenosine receptors, however, synthetic agonists have been shown to directly suppress tumor cell survival and/or proliferation (Fishman et al., 2004) . The antiproliferative effects of A3 agonists most likely rely on the downregulation of A3 adenosine receptors following chronic activation. A3 agonists have been shown to decrease the activity of protein kinase A and Akt, resulting in a suppression of cyclin D1, c-myc and cell proliferation (Fishman et al., 2004) . A3 receptor agonists have also been shown to enhance the antitumor activity of NK cells by IL-12 upregulation (Harish et al., 2003) . Finally, in some circumstances, the pro-apoptotic effects of A3 receptor agonists can be independent of A3 receptor activation (Morello et al., 2008) .
A2A receptors in cancer. The activation of A2A adenosine receptors on endothelial cells significantly enhances tumor angiogenesis (Ahmad et al., 2009) . This is consistent with the fact that endothelial cells associated with tumors have significantly higher levels of A2A adenosine receptors. Analysis of A2A receptor expression in lung cancer samples and matched normal lung tissue revealed that there was a significant increased expression of A2A in early-stage cancer samples (Ahmad et al., 2009) . Other studies have shown that activation of A2A adenosine receptors directly promotes tumor cell survival. Indeed, activation of A2A adenosine receptors was found to significantly enhance the proliferation of the hormone-dependent breast cancer cell line MCF-7 (Etique et al., 2009) .
In addition to its pro-angiogenic and proliferative effects, the A2A adenosine receptor is a potent suppressor of endogenous tumor immunosurveillance. Accordingly, Ohta et al. (2006) showed that A2A receptor-deficient mice mount spontaneous antitumor T-cell responses able to induce T-cell-dependent tumor rejection. This study suggested that blocking A2A receptors enhanced existing antitumor immune responses and increased IFN-g production from antitumor CD8 þ T cells was suggested as the main mechanism of action.
A2B receptors in cancer. A2B adenosine receptors also have an important role in angiogenesis (Feoktistov et al., 2002) . The pro-angiogenic effect of A2B receptors is due to its expression on both endothelial and hematopoietic cells. Accordingly, studies in A2B-deficient mice have shown that tumor-infiltrating CD45 þ cells, most likely CD11b þ myeloid cells, produce up to fivefold more vascular endothelial growth factor when proficient in A2B adenosine receptors . The expression of A2B adenosine receptors on mast cells may also significantly enhance tumor angiogenesis. The stimulation of A2B adenosine receptors in mast cells has been shown to induce the production of IL-4, IL-13, IL-8 and vascular endothelial growth factor .
Modulating purinergic signaling for cancer therapy ATP release and immunogenic chemotherapy Specific classes of chemotherapeutic drugs, such as anthracyclines, have recently been shown to be potent inducers of immunogenic cancer cell death, thereby triggering antitumor immune responses (Ghiringhelli et al., 2009) (Figure 3 ). Most remarkably, the antitumor immune responses induced by these specific chemotherapeutic drugs were shown to be essential for therapeutic activity in mice. Intriguingly, drugs such as anthracyclines and oxaliplatin induce potent immunogenic cell death, whereas other drugs, such as etoposide and mitomycin C, fail to do so. In an attempt to elucidate the mechanism of immunogenic chemotherapy, Obeid et al. (2007) showed that pro-inflammatory apoptosis of tumor cells was directly linked to the rapid translocation of calreticulin (CRT) to the cell surface upon exposure to the drug. Dying tumor cells must thus translocate the endoplasmic reticulum-resident CRT and disulfide isomerase ERp57 to the plasma membrane to be efficiently phagocytosed by DCs. In addition to CRT translocation, the release of chromatin-binding high-mobility group box 1 protein by dying tumor cells and its activation of TLR4 on DCs are also required . However, the addition of recombinant CRT and high-mobility group box 1 to live tumor cells is not sufficient to induce antitumor immune responses, implying another level of regulation. As activation of inflammasomes is central to the instigation of immune responses, Zitvogel and colleagues hypothesized that the NLRP3 inflammasome may constitute a third level of regulation of immunogenic chemotherapy (Ghiringhelli et al., 2009) . Zitvogel and colleagues recently showed that activation of the NLRP3 inflammasome in DCs is indeed a critical event in the induction of antitumor immune responses following treatment with doxorubicin, mitoxanthrone and oxaliplatin (Ghiringhelli et al., 2009) . Ghiringhelli et al. (2009) further tested whether the release of ATP from dying tumor cells was involved in the activation of the NLRP3 inflammasome. Numerous chemotherapeutic drugs-that is, cadmium, etoposide, mitomycin C, oxaliplatin, cisplatin, staurosporine, thapsigargin, mitoxanthrone and doxorubicin-could indeed trigger the release of extracellular ATP from tumor cells before and during apoptosis (Martins et al., 2009) . Remarkably, mice deficient in the ATP receptor P2X 7 bearing EL4 or EG7 tumors failed to respond to oxaliplatin treatment and failed to mount tumor-specific CD8 þ T-cell responses, a phenotype that could be rescued by the adoptive transfer of wild-type DCs. Taken together, these studies strongly suggest that anthracyclines and oxaliplatin induce immunogenic cell death by the translocation of CRT on tumor cells and the activation, on DCs, of TLR4 by high-mobility group box 1 and P2X 7 by ATP release. These events in turn activate the NLRP3 inflammasome in DCs, stimulate antigen presentation and IL-1b release, thereby generating IFN-g-producing tumor-specific CD8 þ T cells. Figure 3 Modulating purinergic signaling for cancer therapy. Altering the balance between extracellular adenosine triphosphate (ATP) and adenosine can induce anticancer activity. Anthracyclines and oxaliplatin trigger ATP release, calreticulin (CRT) translocation and high-mobility group box 1 (HMGB1) release from tumor cells, thereby activating NLRP3 inflammasome and inducing antitumor immune responses that are essential for therapeutic activity (Ghiringhelli et al., 2009) . However, tumor cells often overexpress ecto-nucleotidases, such as CD39 and CD73, which hydrolyze extracellular ATP to adenosine. Two recent studies, including our own work, have identified tumor-derived CD73 as an important mechanism of tumor immune escape (Stagg et al., 2010) . Antibody-based therapy against CD73 can significantly inhibit tumor growth, chemotaxis and metastasis, suggesting that CD73 may constitute a potential cancer target.
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Blocking A2A adenosine receptors As discussed above, Ohta et al. (2006) showed that mice genetically deficient in A2A receptors are significantly protected against CL8-1 and RMA tumor challenges, most likely by enhanced antitumor CD8 þ T-cell response. The authors of that study also tested whether pharmacological inhibition of A2A receptors could induce antitumor activity in wild-type mice. Indeed, injection of A2A antagonists significantly enhanced the therapeutic activity of adoptively transferred tumorspecific CD8 þ T cells. No therapeutic effect was observed against non-immunogenic B16 tumors, or in nude mice with CL8-1 tumors, suggesting a T-celldependent mechanism. Interestingly, pharmacological inhibition of A2A receptors was associated with the development of self-resolving autoimmunity as evidenced by transient hair loss. As pointed out by the authors, 'it is important to carefully consider the known cardiovascular and neurological effects of A2A and A2B antagonists'. Potential side effects of A2A receptor antagonists might include increased blood pressure and inflammation. However, based on the results of recent clinical trials with A2A receptor antagonists against Parkinson's disease, A2A antagonists seem to be welltolerated (LeWitt et al., 2008) .
Targeting CD73
Although pharmacological antagonists to adenosine receptors may hold therapeutic potential, an alternative is to target the ecto-nucleotidase CD73. The observation that CD73 is expressed at high levels in various types of cancer supports this approach. Using RNA-interference knockdown of CD73, we have recently shown that CD73 expression by breast tumor cells significantly impairs adaptive antitumor immune responses (Stagg et al., 2010) . Another independent group recently corroborated our findings, revealing that tumor-derived CD73 inhibited T-cell immunosurveillance of murine ovarian tumors (Jin et al., 2010) . The latter study showed that CD73 on tumor cells inhibited T-cell function and induced T-cell apoptosis.
We have investigated whether CD73 could be a potential target for antibody-based therapy (clone TY/23). Tumors of treated mice were significantly reduced in size compared with control-treated mice (Stagg et al., 2010) . As 4T1.2 tumors can spontaneously metastasize after injection in the mammary fat pad, we also observed that anti-CD73 monoclonal antibody treatment significantly reduced the number of spontaneous lung metastases. Our data also revealed that CD73-derived adenosine enhanced tumor cell chemotaxis. Others had previously shown that CD73 expression in breast cancer cells was associated with increased migration (Zhi et al., 2007) . Our data further suggested a role for A2B adenosine receptors in tumor cell metastasis. A2B receptors could potentially enhance chemokine receptor expression (Richard et al., 2006) or act as an important co-receptor. Accordingly, A2B adenosine receptors have been shown to promote human colon cancer cell motility by a mechanism involving co-activation of the dependence receptor DCC (Rodrigues et al., 2007) .
Conclusion
One of the most important consequences of tumorigenesis is the disruption of tissue architecture. Among other pathways, tissue damage triggers the release of extracellular ATP, which activates P2X and P2Y receptors to promote tissue repair. The activation of ATP receptors enhances cell survival, proliferation and migration, and acts as a chemotactic molecule for the recruitment of immune phagocytes and DCs. In the presence of dangerassociated molecules, extracellular ATP further activates NLRP3 inflammasomes, thereby triggering a pro-inflammatory cascade leading to the activation of innate and adaptive immune responses. Concurrently, regulatory mechanisms are in place to prevent excessive tissue damage that might be caused by unresolved inflammation. Tissue hypoxia and the accumulation of specific cytokines, such as type I IFNs and TNF-a, are important activators of these regulatory mechanisms. One of the most important immunosuppressive regulatory pathways is the phosphohydrolysis of extracellular ATP to adenosine.
In the context of cancer, tumor cells can directly exploit ATP and adenosine receptors for survival, proliferation and motility. In addition, tumor cells have been found to express high levels of ecto-nucleotidases, such as CD73, that catabolize the formation of extracellular adenosine. Extracellular adenosine generated from the activity of CD73 promotes tumor angiogenesis, immune escape and metastasis. The accumulation of extracellular adenosine thus constitutes an important regulatory mechanism in the generation of antitumor immunity. Our data and that of others strongly suggest that the ecto-nucleotidase CD73 may constitute a previously unrecognized target for cancer therapy.
It has become increasingly evident that antitumor immune responses are essential not only for the endogenous control of tumorigenesis, but also for the therapeutic activity of standard treatment, such as chemotherapy. However, several regulatory mechanisms, or 'immune-checkpoints', limit the generation of anticancer immune responses. Various strategies targeting specific immune-checkpoints can be deployed to enhance antitumor immunity. Understanding the relative importance of each of these immune-checkpoints in specific cancer types in the context of patients' individual polymorphism will be of primary importance. Thorough translational studies will thus be essential for the development of safe and effective new cancer treatments aiming to harness antitumor immune responses.
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